JPM 2026
Taiwan’s Biotech Leaders Double Down on AI and US Manufacturing: Inside Bora and EirGenix’s Strategic Roadmaps
2026-02-03
From Capacity Upgrades to Tech Licensing: Global Strategies of Samsung Biologics, Celltrion, and Alteogen
2026-01-21
JPM 2026 Reveals Biopharma’s High-Stakes Mix of IPO Risk, Market Turbulence, and Regulation
2026-01-19
Beyond the Main Stage: A Showcase of the Next Wave of Korean Biotech Innovation at JPM Week 2026
2026-01-15
JPM 2026 Recap: Capital Markets Reopen, AI Moves to the Last Mile, Metabolic Stakes Climb
2026-01-15
AbbVie Bets $5.6 Billion on PD-1×VEGF Bispecifics, Licensing RemeGen’s RC148 to Expand Its Oncology Arsenal
2026-01-13
JP Morgan 2026: Eight Companies’ Clinical Milestones across tRNA Medicines, Immune Reset, and Oncology
2026-01-13
From Main Venue Presentations to Strategic Partnering, Taiwan’s Biotech Sector Makes Its Mark in JPM 2026
2026-01-13
First-of-Its-Kind AI Drug Discovery Lab: NVIDIA, Eli Lilly Announce $1B Investment at J.P. Morgan Healthcare
2026-01-12
LATEST
Trip.com Group Limited to Release Q4 and Full-Year 2025 Financial Results on February 25, 2026
2026-02-09
FireFox Gold Reports 54.91 g/t Gold Over 1.95 Meters in Northeast Zone Expansion at Mustajärvi Project
2026-02-09



